Zhang, Hong
Daoud, Sami Z.
Gillen, Michael S.
Calderon, Natalia
Heijer, Maria
Molins, Eduard
Garcia-Gil, Esther
Chen, Hong
Li, Qianqian
Liu, Chengjiao
Ding, Yanhua
Clinical trials referenced in this document:
Documents that mention this clinical trial
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
https://doi.org/10.1007/s40268-021-00374-z
Funding for this research was provided by:
National Major Scientific and Technological Special Project for Significant New Drug Development (2017ZX09304004, 2017ZX09101001-002-004)
National Natural Science Foundation of China (81602897)
National Major Scientific and Technological Special Project for Significant New Drugs Development (2018ZX09301007005)
AstraZeneca
Article History
Accepted: 28 November 2021
First Online: 8 February 2022
Declarations
:
: This work was supported by the National Major Scientific and Technological Special Project for Significant New Drug Development during the Thirteenth Five-Year Plan Period of China (Project: 2017ZX09304004, 2017ZX09101001-002-004), the National Natural Science Foundation of China (Project: 81602897), and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-Year Plan Period of China (No. 2018ZX09301007005). Further funding was received from AstraZeneca.
: Sami Z. Daoud, Michael S. Gillen, Maria Heijer and Eduard Molins are employed by AstraZeneca, and Esther Garcia-Gil and Natalia Calderon are former employees of AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This manuscript has associated data in a repository. Data underlying the findings described in this manuscript, including individual de-identified participant data, protocols and clinical trial documents, may be obtained in accordance with AstraZeneca’s data-sharing policy (described at ExternalRef removed) through Vivli (ExternalRef removed).
: Not applicable.
: Sami Z. Daoud, Michael S. Gillen, Natalia Calderon, Eduard Molins, and Esther Garcia-Gil contributed to the conception and design of the study; Hong Zhang, Hong Chen, Qianqian Li, and Yanhua Ding contributed to the design of the study; Hong Zhang, Hong Chen, Qianqian Li, Chengjiao Liu, and Yanhua Ding performed the study; and Hong Zhang and Yanhua Ding developed the first draft. All authors contributed to the interpretation and revision of the manuscript for intellectual content and provided final approval.
: The Institutional Review Board of The First Hospital of Jilin University reviewed and approved the final protocol, any amendments, and the informed consent documentation. The study was performed in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines, and conformed with local regulatory requirements.
: All patients provided written, informed consent prior to the conduct of any study-specific procedures.
: Not applicable.